Physician profile
Joseph David
NPI 1700874310
$12,712.07
in general payments reported to CMS, 2019-2025
16 companies · $3,638 in 2025
The $3,638 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.55 · 2021: $64.13 · 2022: $302 · 2023: $575 · 2024: $8,035 · 2025: $3,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,775 · Food and Beverage: $1,575 · Travel and Lodging: $839 · Education: $59.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,775.00 |
| Food and Beverage | $1,574.61 |
| Travel and Lodging | $838.86 |
| Education | $59.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $10,613.86 | 2024-2025 | Omvoh |
| Lilly USA, LLC | $707.57 | 2023-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.76 | 2019-2024 | Trulance, Xifaxan, Plenvu |
| E.R. Squibb & Sons, L.L.C. | $263.74 | 2022-2023 | Zeposia |
| Abbvie INC. | $241.93 | 2019-2023 | Rinvoq |
| Janssen Biotech, INC. | $152.48 | 2021-2024 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2025 | Iqirvo |
| Novo Nordisk INC | $104.05 | 2025 | Wegovy |
| Medtronic, INC. | $55.58 | 2025 | Gi Genius |
| Celgene Corporation | $27.15 | 2024 | Zeposia |
| Abbott Laboratories | $27.06 | 2024 | Proclaim |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2023 | Dupixent |
| Laborie Medical Technologies Corp. | $21.60 | 2024 | Solar Uroflow System |
| Celltrion USA INC. | $19.16 | 2023 | Yuflyma |
| Ardelyx, INC. | $16.97 | 2023 | Ibsrela |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.